1 In adults with obesity, along with diet and exercise, A well-studied safety profile for adults with obesity: Pooled safety data from 2 weight-management clinical trials evaluating Wegovy HD 7.2 mg 1 Wegovy HD (semaglutide) injection 7.2 mg had a safety profile consistent with Wegovy 2.4 mg 1,3 5% of patients with Wegovy HD 7.2 mg pen, 5% of patients with Wegovy 2.4 mg pen, and 2% of patients with placebo permanently discontinued as a result of adverse reactions 1 The most common adverse reactions leading to discontinuation were gastrointestinal disorders: 3% of patients with Wegovy HD 7.2 mg pen, 3% of patients with Wegovy 2.4 mg pen, and 0.3% of patients with placebo 1 Includes allodynia, burning sensation, dysesthesia, hyperesthesia, hyperpathia, pain of skin, paresthesia, sensitive skin, skin burning sensation, skin discomfort, and skin sensitization
If you're ready to ensure every aspect of your research is held to the highest standard, you can Get Started Today
Humanized receptor mouse models express the human targets of these drug candidates, enabling in vivo efficacy and safety evaluation and helping researchers better predict the clinical performance of new obesity and diabetes therapies
For many people with melasma, glutathione combined with tranexamic acid and azelaic acid provides a safer and more sustainable treatment approach
Data analysis Blinded
Demystifying GLP1 Face Demystifying GLP Face: What Happens to Your Face When You Lose Weight Fast